Genes Predisposing to Type 1 Diabetes Mellitus and Pathophysiology: a Narrative Review Tajudeen Yahaya,¹ Titilola Salisu²

Total Page:16

File Type:pdf, Size:1020Kb

Genes Predisposing to Type 1 Diabetes Mellitus and Pathophysiology: a Narrative Review Tajudeen Yahaya,¹ Titilola Salisu² 100 Med J Indones 2020;29(1) Review Article Genes predisposing to type 1 diabetes mellitus and pathophysiology: a narrative review Tajudeen Yahaya,¹ Titilola Salisu² pISSN: 0853-1773 • eISSN: 2252-8083 ABSTRACT https://doi.org/10.13181/mji.rev.203732 The possibility of targeting the causal genes along with the mechanisms of Med J Indones. 2020;29:100–9 pathogenically complex diseases has led to numerous studies on the genetic etiology Received: April 24, 2019 of some diseases. In particular, studies have added more genes to the list of type 1 Accepted: January 23, 2020 diabetes mellitus (T1DM) suspect genes, necessitating an update for the interest of Authors' affiliations: all stakeholders. Therefore this review articulates T1DM suspect genes and their ¹Department of Biology, Faculty of pathophysiology. Notable electronic databases, including Medline, Scopus, PubMed, Science, Federal University Birnin Kebbi, and Google-Scholar were searched for relevant information. The search identified Kebbi State, Nigeria, ²Department of Zoology and Environmental Biology, over 73 genes suspected in the pathogenesis of T1DM, with human leukocyte antigen, Olabisi Onabanjo University Ago-Iwoye, insulin gene, and cytotoxic T lymphocyte-associated antigen 4 accounting for most of Ogun State, Nigeria the cases. Mutations in these genes, along with environmental factors, may produce Corresponding author: a defective immune response in the pancreas, resulting in β-cell autoimmunity, insulin Tajudeen Yahaya deficiency, and hyperglycemia. The mechanisms leading to these cellular reactions are Department of Biology, Faculty of gene-specific and, if targeted in diabetic individuals, may lead to improved treatment. Science, Federal University Birnin Kebbi, Medical practitioners are advised to formulate treatment procedures that target these Kebbi State, Nigeria Tel/Fax: +234-8033550788/ genes in patients with T1DM. +234-8098233774 E-mail: [email protected]/ KEYWORDS autoimmunity, hyperglycemia, insulin, pancreas, type 1 diabetes mellitus [email protected] Diabetes mellitus (DM) begins when hyperglycemia leading to the retention of glucose in the blood.¹ Some occurs. A hormone synthesized by the pancreatic people develop a condition known as secondary DM, β-cells, known as insulin, regulates blood glucose by which is like T1DM, but the immune system does not transporting it from the bloodstream into the cells destroy the β-cells.² Instead, the cells are removed where it is metabolized. Another hormone produced by by certain stimuli in the pancreas, as indicated by the pancreatic α-cells, known as glucagon, also assists histopathological changes.² T1DM was previously the body in the blood glucose regulation process. In named juvenile DM but was renamed because adults most cases, type 1 diabetes mellitus (T1DM) occurs can also develop the disease. Moreover, T1DM is not when the immune system, which normally attacks the only form of DM that affects children and young only foreign antigens, faultly destroys the β-cells. adults. Particularly, type 2 diabetes mellitus (T2DM) Consequently, the pancreas stops making insulin, is becoming increasingly prevalent among young Copyright @ 2020 Authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http:// creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are properly cited. For commercial use of this work, please see our terms at https://mji.ui.ac.id/journal/index.php/mji/copyright. mji.ui.ac.idMedical Journal of Indonesia Yahaya, et al. | Type 1 diabetes mellitus suspect genes 101 individuals as more and more children are becoming T1DM SUSPECT GENES obese and overweight nowadays.³ Maturity-onset diabetes of the young and neonatal diabetes mellitus At least 18 regions in the human genome were are other forms of DM that mainly affect children and identified as hotspots for T1DM using genome-wide neonates with different clinical features from T1DM. linkage analysis. These regions host many genes T1DM is the most frequent chronic illness among and are labeled IDDM1-IDDM18 because T1DM was children, accounting for 5–10% of all DM cases.² It is the formerly called insulin-dependent DM (IDDM).⁶ most burdensome form of DM, with a decreased life However, improvement in biological techniques has expectancy.⁴ About 30 million people live with T1DM led to a greater understanding of the genetic basis worldwide, and the prevalence is predicted to increase of T1DM. More precise studies have reaffirmed the three-fold in the 2040s.⁵ Uncontrolled T1DM may roles of some previously suspected genes in T1DM cause chronic complications, including retinopathy, pathogenesis and new ones have been discovered. nephropathy, neuropathy, and vascular diseases. Many genes have been reportedly linked with T1DM, T1DM has a strong genetic etiology modulated by but only those with clear mechanisms are presented some environmental triggers that may prevent in this review. Tables 1–3 show the update on the disease if avoided before autoimmunity. The T1DM candidate genes, grouped according to their treatment involves constant insulin injections, which mechanisms of action, which are disruption of is expensive; thus, a better approach is necessary to T cell regulatory activities, increased susceptibility stem the burden of the disease. As autoimmunity to microbial infection, oxidative stress, cytokine- is the hallmark of T1DM, an intervention that induced β-cell loss, and β-cell reconfiguration. re-programs the immune system may be a potential However, more genes are being added continually. way to treat the disease. This observation suggests that precision medicine that targets causal genes and Most frequently suspected T1DM predisposing genes the pathophysiology of complicated diseases, such Of the genes described in Tables 1–3, mutations in as DM, may provide a future management when fully the major histocompatibility complex (MHC), insulin understood. Hence, this review was initiated to search gene (INS), cytotoxic T lymphocyte-associated protein notable electronic databases, including Medline, 4 (CTLA4), protein tyrosine phosphatase, non-receptor Scopus, PubMed, and Google-Scholar to establish type 2 (PTPN2), and protein tyrosine phosphatase, T1DM suspected genes. The result will facilitate the non-receptor type 22 (PTPN22) genes account for formulation of drugs and treatment procedures that most of the T1DM cases. Detailed information on target these genes and their mechanisms. the diabetogenic activities of these genes is given below. Table 1. T1DM suspect genes that disrupt T cell immune regulatory activities and increase susceptibility to microbial infection Gene Full name Locus Mechanism Cytotoxic Causes massive lymphocyte proliferation, resulting in overexpression of T cells, CTLA4 T-lymphocyte 2q33.2 which attack self-antigens, leading to β-cell apoptosis.⁷ associated protein 4 Disrupts the activities of many endocrine glands, affecting the immune regulatory FOXP3 Forkhead box P3 Xp11.23 T cells and setting of autoimmunity.⁸ Protein kinase C PRKCQ 10p15.1 Loss of T cell signaling, leading to a compromised immune system.⁹ theta Interleukin 7 IL7R 5p13.2 Causes a compromised immune system, characterized by depletion of T cells.¹⁰ receptor IL2 Interleukin 2 4q27 Causes functional loss of T cell (Treg) regulation, resulting in autoimmunity.¹¹ Integrin subunit ITGB7 12q13.13 It disrupts the activities of T cells in the pancreas, resulting in autoimmunity.¹² beta 7 SH2B adaptor SH2B3 12q24.13 Increases self-reactive T lymphocyte proliferation.¹³ protein 3 RAS guanyl releasing Reduced expression results in splenomegaly and autoantibodies, while complete RASGRP1 15q14 protein 1 deletion decreases T cell development in the thymus.¹⁴ Medical Journal of Indonesia 102 Med J Indones 2020;29(1) Table 1. (continued) Gene Full name Locus Mechanism Mediates loss of function of regulatory T cells, leading to autoimmunity of the CD28 CD28 molecule 2q33.2 pancreatic β-cells.¹⁵ Inducible T cell ICOS 2q33.2 It suppresses insulin-specific regulatory T cells.¹⁶ costimulator Antisense to Causes insulitis in which the islets are massively infiltrated by macrophages and ART2/RT6 ribosomal RNA 11p15.4 T cells.¹⁷ transcript protein 2 Ubiquitin associated Increases UBASH3A expression in CD4+ T cells, disrupting NF-κB signaling, which UBASH3A and SH3 domain 21q22.3 in turn represses IL2 gene expression.¹⁸ containing A Small ubiquitin-like Reduces sumoylation capacity, causing overexpression of NF-κB and IL12B, and SUMO4 6q25.1 modifier 4 leading to β-cell autoimmunity.¹⁹ Major MHC histocompatibility 6p21.31 Causes loss of T cell signaling, leading to autoimmunity of the pancreatic β-cells.²⁰ complex Causes defects in Treg phenotype decreasing its signaling activities, culminating NRP1 Neuropilin 1 10p11.22 in autoimmunity of the β-cells.²¹ Macrophage Causes high MIF concentrations in the blood, resulting in dysfunctional pancreatic MIF migration inhibitory 22q11.23 islets. Also causes loss of function of immune cells, such as macrophages and T factor cells, increasing the risk of β-cell autoimmunity.²² Cluster of Increases the frequency of GAD autoantibody and lowers C-peptide levels, CD226 18q22.2 differentiation 226 accelerating β-cell destruction.²³ Impairs immune response, leading to β-cell autoimmunity, it also leads to IL6 Interleukin
Recommended publications
  • Novel Binding Partners of PBF in Thyroid Tumourigenesis
    NOVEL BINDING PARTNERS OF PBF IN THYROID TUMOURIGENESIS By Neil Sharma A thesis presented to the College of Medical and Dental Sciences at the University of Birmingham for the Degree of Doctor of Philosophy Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine August 2013 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. SUMMARY Thyroid cancer is the most common endocrine cancer, with a rising incidence. The proto-oncogene PBF is over-expressed in thyroid tumours, and the degree of over-expression is directly linked to patient survival. PBF causes transformation in vitro and tumourigenesis in vivo, with PBF-transgenic mice developing large, macro-follicular goitres, effects partly mediated by the internalisation and repression of the membrane-bound transporters NIS and MCT8. NIS repression leads to a reduction in iodide uptake, which may negatively affect the efficacy of radioiodine treatment, and therefore prognosis. Work within this thesis describes the use of tandem mass spectrometry to produce a list of potential binding partners of PBF. This will aid further research into the pathophysiology of PBF, not just in relation to thyroid cancer but also other malignancies.
    [Show full text]
  • Clinical and Biological Features of PTPN2-Deleted Adult and Pediatric T-Cell Acute Lymphoblastic Leukemia
    REGULAR ARTICLE Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia Marion Alcantara,1 Mathieu Simonin,1-3 Ludovic Lhermitte,1 Aurore Touzart,1 Marie Emilie Dourthe,1,4 Mehdi Latiri,1 Nathalie Grardel,5 Jean Michel Cayuela,6 Yves Chalandon,7 Carlos Graux,8 Herve´ Dombret,9 Norbert Ifrah,10 Arnaud Petit,2,3 Elizabeth Macintyre,1 Andre´ Baruchel,4 Nicolas Boissel,9 and Vahid Asnafi1 1Universite´ Paris Descartes Sorbonne Cite,´ Institut Necker-Enfants Malades, Institut National de Recherche Medicale´ U1151, Laboratory of Onco-Hematology, Assistance Publique–Hopitauxˆ de Paris, Hopitalˆ Necker Enfants-Malades, Paris, France; 2Department of Pediatric Hematology and Oncology, Assistance Publique–Hopitauxˆ de Paris, Groupe Hospitalier des Hopitauxˆ Universitaires Est Parisien, Armand Trousseau Hospital, Paris, France; 3Sorbonne Universites,´ Universite´ Pierre et Marie Curie Universite´ Paris 06, Unite´ Mixte de Recherche S 938, Centre de Recherche Saint-Antoine, Groupe de Recherche (GRC) Clinique n°07, GRC Myeloprolif´ erations´ aigues¨ et chroniques, Paris, France; 4Department of Pediatric Hematology and Immunology, Assistance Publique–Hopitauxˆ de Paris, Hopitalˆ Universitaire Robert-Debre,´ Paris, France; 5Laboratory of Hematology, Centre Hospitalier Regional´ Universitaire de Lille, Lille, France; 6Laboratory of Hematology, Saint-Louis Hospital, Assistance Publique–Hopitauxˆ de Paris, Paris, France; 7Swiss Group for Clinical Cancer Research, Bern, Hopitalˆ Universitaire, Geneva, Switzerland; 8Universite´ Catholique de Louvain, Centre Hospitalier Universitaire, Namur, Yvoir, Belgium; 9Adolescent and Young Adult Hematology Unit, Saint-Louis Hospital, Assistance Publique–Hopitauxˆ de Paris, Paris, France; and 10Centre Hospitalier Universitaire d’Angers, Angers, France Protein tyrosine phosphatase nonreceptor type 2 (PTPN2) is a phosphatase known to be Key Points a tumor suppressor gene in T-cell acute lymphoblastic leukemia (T-ALL).
    [Show full text]
  • Renalase — a New Marker Or Just a Bystander in Cardiovascular Disease: Clinical and Experimental Data
    Kardiologia Polska 2016; 74, 9: 937–942; DOI: 10.5603/KP.a2016.0095 ISSN 0022–9032 ARTYKUŁ SPECJALNY / STATE-OF-THE-ART REVIEW Renalase — a new marker or just a bystander in cardiovascular disease: clinical and experimental data Dominika Musiałowska, Jolanta Małyszko 2nd Department of Nephrology, Medical University of Bialystok, Bialystok, Poland Dominika Musiałowska was born in 1985 in Bialystok. She graduated the Medical University of Bialystok in 2010 with the average grade of very good. During her studies she was awarded a scholarship from the Minister of Health for her academic results. She successfully completed a short-term fellowship supported by the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) in modulation of sympathetic nerve activity by renal denerva- tion in hypertensive renal transplant patients in the Nephrology Department in Heinrich Heine Universitat Duesseldorf, Germany (October 1, 2012 – March 29, 2013). She became a Doctor of Philosophy in 2014 after a public defence of her manuscript Renalase concentration in hypertensive patients. She works in 2nd Department of Nephrology at the Medical University of Bialystok, Poland. Jolanta Małyszko graduated with merit from the Medical University of Bialystok, Poland. She is a full Professor (2002) and from 2013 a chairman of 2nd Department on Nephrology, Medical University, Bialystok, Poland. Her clinical training was performed in the Intensive Care Unit and Nephrology Department, CHU Rouen, France, Nephrology Department, Heinrich-Heine Uni- versity, Dusseldorf, Germany (ERA-EDTA clinical scholarship), McKennon Hospital, Sioux Falls, South Dakota, United States (invasive cardiology), Kings’ College, London, United Kingdom, and Sourasky Hospital, Israel. During a Japanese Ministry of Education scholarship at Hamamatsu University School of Medicine she defended her PhD thesis on the role of FK 506 in transplanta- tion in 1995.
    [Show full text]
  • Gene Loci Associated with Insulin Secretion in Islets from Nondiabetic Mice
    Gene loci associated with insulin secretion in islets from nondiabetic mice Mark P. Keller, … , Gary A. Churchill, Alan D. Attie J Clin Invest. 2019;129(10):4419-4432. https://doi.org/10.1172/JCI129143. Research Article Cell biology Genetics Graphical abstract Find the latest version: https://jci.me/129143/pdf The Journal of Clinical Investigation RESEARCH ARTICLE Gene loci associated with insulin secretion in islets from nondiabetic mice Mark P. Keller,1 Mary E. Rabaglia,1 Kathryn L. Schueler,1 Donnie S. Stapleton,1 Daniel M. Gatti,2 Matthew Vincent,2 Kelly A. Mitok,1 Ziyue Wang,3 Takanao Ishimura,2 Shane P. Simonett,1 Christopher H. Emfinger,1 Rahul Das,1 Tim Beck,4 Christina Kendziorski,3 Karl W. Broman,3 Brian S. Yandell,5 Gary A. Churchill,2 and Alan D. Attie1 1University of Wisconsin-Madison, Biochemistry Department, Madison, Wisconsin, USA. 2The Jackson Laboratory, Bar Harbor, Maine, USA. 3University of Wisconsin-Madison, Department of Biostatistics and Medical Informatics, Madison, Wisconsin, USA. 4Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom. 5University of Wisconsin-Madison, Department of Horticulture, Madison, Wisconsin, USA. Genetic susceptibility to type 2 diabetes is primarily due to β cell dysfunction. However, a genetic study to directly interrogate β cell function ex vivo has never been previously performed. We isolated 233,447 islets from 483 Diversity Outbred (DO) mice maintained on a Western-style diet, and measured insulin secretion in response to a variety of secretagogues. Insulin secretion from DO islets ranged greater than 1000-fold even though none of the mice were diabetic.
    [Show full text]
  • Inflammatory Cytokine Signalling by Protein Tyrosine Phosphatases in Pancreatic Β-Cells
    59 4 W J STANLEY and others PTPN1 and PTPN6 modulate 59: 4 325–337 Research cytokine signalling in β-cells Differential regulation of pro- inflammatory cytokine signalling by protein tyrosine phosphatases in pancreatic β-cells William J Stanley1,2, Prerak M Trivedi1,2, Andrew P Sutherland1, Helen E Thomas1,2 and Esteban N Gurzov1,2,3 Correspondence should be addressed 1 St. Vincent’s Institute of Medical Research, Melbourne, Australia to E N Gurzov 2 Department of Medicine, St. Vincent’s Hospital, The University of Melbourne, Melbourne, Australia Email 3 ULB Center for Diabetes Research, Universite Libre de Bruxelles (ULB), Brussels, Belgium esteban.gurzov@unimelb. edu.au Abstract Type 1 diabetes (T1D) is characterized by the destruction of insulin-producing β-cells Key Words by immune cells in the pancreas. Pro-inflammatory including TNF-α, IFN-γ and IL-1β f pancreatic β-cells are released in the islet during the autoimmune assault and signal in β-cells through f protein tyrosine phosphorylation cascades, resulting in pro-apoptotic gene expression and eventually phosphatases β-cell death. Protein tyrosine phosphatases (PTPs) are a family of enzymes that regulate f PTPN1 phosphorylative signalling and are associated with the development of T1D. Here, we f PTPN6 observed expression of PTPN6 and PTPN1 in human islets and islets from non-obese f cytokines diabetic (NOD) mice. To clarify the role of these PTPs in β-cells/islets, we took advantage f inflammation Journal of Molecular Endocrinology of CRISPR/Cas9 technology and pharmacological approaches to inactivate both proteins. We identify PTPN6 as a negative regulator of TNF-α-induced β-cell death, through JNK- dependent BCL-2 protein degradation.
    [Show full text]
  • The Expression Patterns and the Prognostic Roles of PTPN Family Members in Digestive Tract Cancers
    Preprint: Please note that this article has not completed peer review. The expression patterns and the prognostic roles of PTPN family members in digestive tract cancers CURRENT STATUS: UNDER REVIEW Jing Chen The First Affiliated Hospital of China Medical University Xu Zhao Liaoning Vocational College of Medicine Yuan Yuan The First Affiliated Hospital of China Medical University Jing-jing Jing The First Affiliated Hospital of China Medical University [email protected] Author ORCiD: https://orcid.org/0000-0002-9807-8089 DOI: 10.21203/rs.3.rs-19689/v1 SUBJECT AREAS Cancer Biology KEYWORDS PTPN family members, digestive tract cancers, expression, prognosis, clinical features 1 Abstract Background Non-receptor protein tyrosine phosphatases (PTPNs) are a set of enzymes involved in the tyrosyl phosphorylation. The present study intended to clarify the associations between the expression patterns of PTPN family members and the prognosis of digestive tract cancers. Method Expression profiling of PTPN family genes in digestive tract cancers were analyzed through ONCOMINE and UALCAN. Gene ontology enrichment analysis was conducted using the DAVID database. The gene–gene interaction network was performed by GeneMANIA and the protein–protein interaction (PPI) network was built using STRING portal couple with Cytoscape. Data from The Cancer Genome Atlas (TCGA) were downloaded for validation and to explore the relationship of the PTPN expression with clinicopathological parameters and survival of digestive tract cancers. Results Most PTPN family members were associated with digestive tract cancers according to Oncomine, Ualcan and TCGA data. For esophageal carcinoma (ESCA), expression of PTPN1, PTPN4 and PTPN12 were upregulated; expression of PTPN20 was associated with poor prognosis.
    [Show full text]
  • The Regulatory Roles of Phosphatases in Cancer
    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
    [Show full text]
  • WO 2018/102612 Al 07 June 2018 (07.06.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/102612 Al 07 June 2018 (07.06.2018) W !P O PCT (51) International Patent Classification: Published: CI2N 15/66 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US20 17/064075 claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (22) International Filing Date: — with sequence listing part of description (Rule 5.2(a)) 30 November 20 17 (30. 11.201 7) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 62/429,709 02 December 20 16 (02.12.20 16) US (71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400 Dexter Ave. North, Suite 1200, Seattle, WA 98109 (US). (72) Inventor: LEVITSKY, Hyam I.; 400 Dexter Ave. North, Suite 1200, Seattle, WA 98109 (US). (74) Agent: AIKEN, Charity et al; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance
    ORIGINAL RESEARCH published: 18 August 2020 doi: 10.3389/fimmu.2020.01856 Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance Larissa Hering 1, Egle Katkeviciute 1, Marlene Schwarzfischer 1, Philipp Busenhart 1, Claudia Gottier 1, Dunja Mrdjen 2, Juliana Komuczki 2†, Marcin Wawrzyniak 1, Silvia Lang 1, Kirstin Atrott 1, Burkhard Becher 2, Gerhard Rogler 1,3, Michael Scharl 1,3* and Marianne R. Spalinger 1 1 Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2 Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland, 3 Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland Edited by: Michele Marie Kosiewicz, University of Louisville, United States Protein tyrosine phosphatase non-receptor type 2 (PTPN2) plays a pivotal role in Reviewed by: immune homeostasis and has been associated with human autoimmune and chronic Cong-Yi Wang, inflammatory diseases. Though PTPN2 is well-characterized in lymphocytes, little is Tongji Medical College, China Andrew L. Mellor, known about its function in innate immune cells. Our findings demonstrate that dendritic Newcastle University, United Kingdom cell (DC)-intrinsic PTPN2 might be the key to explain the central role for PTPN2 in *Correspondence: the immune system to maintain immune tolerance. Partial genetic PTPN2 ablation in Michael Scharl DCs resulted in spontaneous inflammation, particularly in skin, liver, lung and kidney 22 [email protected] weeks post-birth. DC-specific PTPN2 controls steady-state immune cell composition † Present address: and even incomplete PTPN2 deficiency in DCs resulted in enhanced organ infiltration of Juliana Komuczki, Roche Innovation Center Basel, conventional type 2 DCs, accompanied by expansion of IFNγ-producing effector T-cells.
    [Show full text]
  • Abstract Renalase Is a Flavoprotein Recently Discovered in Humans
    Abstract Renalase is a flavoprotein recently discovered in humans, which is ubiquitous in vertebrates and conserved in some other phyla. In 2005, it was identified within a project aimed to determine novel proteins secreted by the kidney, whose defect could explain the high incidence of cardiovascular complications in patients with chronic kidney disease (Xu et al., 2005). The protein is preferentially expressed in the renal proximal tubules and heart, and it’s secreted in blood and urine. Genetic, epidemiological, clinical studies and animal experimental models have constantly accumulated evidence of the important role played by renalase in lowering blood pressure, decreasing the catecholaminergic tone and control heart function. A renalase knockout mouse model resulted in increased levels of catecholamines in plasma and heart, cardiac ischemia and myocardial necrosis more severe than WT littermates (Wu et al., 2011). However, the possible molecular mechanism, the nature of the in vivo catalyzed reaction and the identity of renalase substrate(s) are still unclear. Based on these premises, the main aim of the project was to provide a detailed biochemical and structural characterization of renalase in order to better elucidate its physiological function. We solved the crystallographic structure of recombinant human renalase at 2.5 Å resolution. The general fold classified it as a member of the p- hydroxybenzoate hydroxylase family. Renalase contains non-covalently bound FAD with redox features suggestive of a oxidase or NAD(P)H- dependent monooxygenase activity (Milani et al., 2011), in contrast with the - proposed activity of catecholamine degradation via a superoxide (O2 )- dependent mechanism (Farzaneh-Far et al., 2010).
    [Show full text]
  • 1 Supplemental Methods in Vivo Mouse Studies
    Supplemental Methods In vivo mouse studies – A subset of WT and qv4J animals were administered the STAT3 inhibitor S3I-201 in-vivo at 20mg/kg daily intraperitoneal for 14 days (1). Transaortic constriction (TAC) was performed on a subset of WT mice for 6 weeks to induce chronic pressure-overload and heart failure, as described (1, 2). Cardiac performance was assessed prior to surgery and at 6 weeks post TAC using Vevo 2100 (Visualsonics). Specifically, cardiac function was determined using the MS-400 transducer in the short axis M-mode. For heart extractions, mice were anesthetized with 2.5% gaseous isoflurane and oxygen and sacrificed with confirmation by the absence of response to probing of the lower extremities. Immunoblot analysis – Primary ventricular cardiac fibroblast lysate was analyzed using SDS-PAGE and immunoblotting, as described (1, 3, 4). Briefly, equal protein loading was achieved using standard BCA protein assay protocols and verified by Ponceau staining of immunoblots. The following antibodies were used for immunoblotting: Total STAT3 (1:1000, Cell Signaling, Catalog #: 4904), vimentin (1:1000, Abcam, Catalog # ab92547:) and GAPDH (1:5000, Fitzgerald, Catalog #: 10R-G109A). Immunofluorescence – Cardiac fibroblasts were seeded in 35 mm Matex glass bottom dishes until ~50-70% confluency. Cells were then fixed in 4% paraformaldehyde and permeabilized with TritonX-100 for 10 mins. Non-specific binding was blocked using blocking buffer comprised of 1.5% bovine serum albumin (BSA), 3% goat serum in 1xPBS ° (Invitrogen) overnight at 4 C. Primary antibodies [βIV-spectrin (1:100, Millipore, Clone# N393/76), total STAT3 (1:100, Cell Signaling, Catalog#: 4904), plakoglobin/anti-gamma catenin (1:400, Abcam, Catalog #: ab15153)] were prepared in blocking buffer and added for overnight incubation at 4°C.
    [Show full text]